Calvin Ha

Calvin Ha

Auto-generated profile, based on publicly available information

Calvin Ha

Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Nature Communications
Verified
Journal Article
Open access
RARimjhim Agarwal
Rimjhim Agarwal
CHCalvin Ha
Calvin Ha
FCFernanda H. Côrtes
Fernanda H. Côrtes
YLYe Ji Lee
Ye Ji Lee
AMAmparo Martínez-Pérez
Amparo Martínez-Pérez
DWDaniela Weiskopf
Daniela Weiskopf
Chikungunya virus (CHIKV), a mosquito-borne alphavirus, causes acute febrile illness that can progress into chronic arthritis-like disease (CHIKVD) in humans. CD4+ T cells have important functions in CHIKV infection, yet the CHIKV target proteins for these CD4 + T cells are poorly characterized. Here, by stimulating PBMCs collected from individuals with chronic CHIKVD with peptides spanning the entire CHIKV proteome, we provide a comprehensive landscape of CHIKV CD4+ T cell epitopes. We identify three immunodominant regions and associated core motifs in CHIKV E1, nsP1 and CP proteins. In addition, by in silico assessment of the sequence conservation of CHIKV proteome with closely related alphaviruses, we define CHIKV epitopes conserved across arthritogenic and encephalitic viruses. Overall, our work describes CD4+ T cell targets of CHIKV in humans, thereby assisting in studying the functions of CD4+ T cells in CHIKV pathogenesis and vaccine design.

25 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
RARimjhim Agarwal
Rimjhim Agarwal
CHCalvin Ha
Calvin Ha
FCFernanda H. Cortes
Fernanda H. Cortes
YLYeji Lee
Yeji Lee
AMAmparo Martínez-Pérez
Amparo Martínez-Pérez
DWDaniela Weiskopf
Daniela Weiskopf
Chikungunya virus (CHIKV), a mosquito-borne alphavirus, causes acute febrile illness that can progress into chronic chikungunya virus disease (CHIKVD) marked by persistent debilitating arthralgia. At present, the exact cause of chronic CHIKVD is not understood, and in humans, the targets of CD4 + T cells in CHIKV are currently unknown. Here, by stimulating peripheral blood mononuclear cells (PBMCs) collected from patients suffering from chronic CHIKVD with peptides spanning the entire CHIKV genome, we provide a comprehensive landscape of CHIKV CD4 + T cell epitopes. We identified 123 novel CD4 + T cell epitopes and three immunodominant regions in E1, nsP1 and CP proteins. The immunodominance of these E1, nsP1 and CP regions was mapped to optimal epitopes, characterized by the capacity to bind to many common HLA class II allelic variants. In addition, we designed and validated a new CHIKV-specific CD4 + T cell epitope megapool, spanning both structural and non-structural proteins, which can be a useful tool to study CHIKV-specific T cell responses in small blood volumes, typically available in pediatric or clinical samples. Finally, by in silico assessment of the conservation of the CHIKV proteome in a diverse set of alphaviruses, we defined CHIKV epitopes conserved across arthritogenic and encephalitic viruses. Overall, our work is the first to identify CD4 + T cell targets of CHIKV in humans, expanding our capacity to study the role of T cells in CHIKV pathogenesis and mapping targets of alphaviruses for vaccine design.